share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股SEC公告 ·  2024/09/17 05:32

Moomoo AI 已提取核心訊息

ZyVersa Therapeutics has entered into a Sales Agreement with A.G.P./Alliance Global Partners on September 16, 2024, establishing an at-the-market (ATM) offering program with an aggregate offering price of up to $1,397,396. Under the agreement, A.G.P. will serve as the sales agent and receive a 3% commission on gross proceeds from share sales.The shares will be sold at prevailing market prices through methods permitted under Rule 415(a)(4) of the Securities Act. The offering is being conducted pursuant to the Company's effective S-3 shelf registration statement filed with the SEC. While there is no minimum offering amount required, the agreement will automatically terminate upon reaching the maximum offering amount.The Company plans to use the net proceeds for working capital and general corporate purposes, including administrative and research and development expenses. The agreement includes standard termination provisions and allows either party to suspend or terminate the offering under specified conditions.
ZyVersa Therapeutics has entered into a Sales Agreement with A.G.P./Alliance Global Partners on September 16, 2024, establishing an at-the-market (ATM) offering program with an aggregate offering price of up to $1,397,396. Under the agreement, A.G.P. will serve as the sales agent and receive a 3% commission on gross proceeds from share sales.The shares will be sold at prevailing market prices through methods permitted under Rule 415(a)(4) of the Securities Act. The offering is being conducted pursuant to the Company's effective S-3 shelf registration statement filed with the SEC. While there is no minimum offering amount required, the agreement will automatically terminate upon reaching the maximum offering amount.The Company plans to use the net proceeds for working capital and general corporate purposes, including administrative and research and development expenses. The agreement includes standard termination provisions and allows either party to suspend or terminate the offering under specified conditions.
ZyVersa Therapeutics於2024年9月16日與A.G.P./Alliance Global Partners簽署銷售協議，建立一個高達1,397,396美元的市場出售（ATM）提供計劃。根據協議，A.G.P.將擔任銷售代理，並獲得出售股票毛收入的3%佣金。股票將在允許的市場價格下通過證劵法第415(a)(4)條款的協議方法出售。該發行是根據公司提交給美國證券交易委員會的有效S-3架構註冊聲明進行的。雖然沒有最低發行金額的要求，但一旦達到最大發行金額，協議將自動終止。公司計劃將淨收益用於營運資金和一般企業用途，包括行政和研發費用。該協議包含標準的終止條款，並允許任何一方在特定條件下暫停或終止發行。
ZyVersa Therapeutics於2024年9月16日與A.G.P./Alliance Global Partners簽署銷售協議，建立一個高達1,397,396美元的市場出售（ATM）提供計劃。根據協議，A.G.P.將擔任銷售代理，並獲得出售股票毛收入的3%佣金。股票將在允許的市場價格下通過證劵法第415(a)(4)條款的協議方法出售。該發行是根據公司提交給美國證券交易委員會的有效S-3架構註冊聲明進行的。雖然沒有最低發行金額的要求，但一旦達到最大發行金額，協議將自動終止。公司計劃將淨收益用於營運資金和一般企業用途，包括行政和研發費用。該協議包含標準的終止條款，並允許任何一方在特定條件下暫停或終止發行。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Plus Therapeutics
    PSTV
    -- 1.4400
    Forte Biosciences
    FBRX
    -- 7.931
    IO Biotech
    IOBT
    -- 1.250
    Actuate Therapeutics
    ACTU
    -- 8.170
    Rallybio
    RLYB
    -- 0.690
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    中概股財報季火熱：驚喜盈利能否延續漲勢？
    1. 哪些行業可能成為本輪財報季的市場焦點？ 2. 在政府強調科技創新和可持續發展的背景下，你認為哪些行業具有最大的增長潜力？ 展开
    中國兩會：會議前後股票價格變動的關鍵要點